Incyte has announced encouraging top-line findings from its pivotal Phase III frontMIND trial, evaluating tafasitamab (marketed as Monjuvi/Minjuvi) in combination with lenalidomide and the standard R-CHOP regimen for newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients at higher risk.
The study compared this combination against R-CHOP alone in adults with elevated International Prognostic Index (IPI) scores. Results showed the trial met its primary endpoint of progression-free survival (PFS), achieving a hazard ratio of 0.75 (95% CI: 0.59–0.96; p=0.019) under Lugano 2014 criteria. The key secondary endpoint, event-free survival (EFS), was also met, and no new safety concerns emerged.
Dr. Steven Stein, Chief Medical Officer at Incyte, highlighted the potential of this regimen to improve outcomes for high-risk patients, noting that current first-line treatments often fall short. The company plans to engage with global regulators to advance this therapy as a new option for DLBCL.
